These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

651 related items for PubMed ID: 16322258

  • 21. Adrenomedullin, an autocrine/paracrine factor induced by androgen withdrawal, stimulates 'neuroendocrine phenotype' in LNCaP prostate tumor cells.
    Berenguer C, Boudouresque F, Dussert C, Daniel L, Muracciole X, Grino M, Rossi D, Mabrouk K, Figarella-Branger D, Martin PM, Ouafik L.
    Oncogene; 2008 Jan 17; 27(4):506-18. PubMed ID: 17637748
    [Abstract] [Full Text] [Related]

  • 22. Overexpressed androgen receptor linked to p21WAF1 silencing may be responsible for androgen independence and resistance to apoptosis of a prostate cancer cell line.
    Wang LG, Ossowski L, Ferrari AC.
    Cancer Res; 2001 Oct 15; 61(20):7544-51. PubMed ID: 11606392
    [Abstract] [Full Text] [Related]

  • 23. Castration-induced apoptosis of androgen-dependent shionogi carcinoma is associated with increased expression of genes encoding insulin-like growth factor-binding proteins.
    Nickerson T, Miyake H, Gleave ME, Pollak M.
    Cancer Res; 1999 Jul 15; 59(14):3392-5. PubMed ID: 10416600
    [Abstract] [Full Text] [Related]

  • 24. Suppression of prostate tumor cell growth in vivo by WT1, the Wilms' tumor suppressor gene.
    Fraizer G, Leahy R, Priyadarshini S, Graham K, Delacerda J, Diaz M.
    Int J Oncol; 2004 Mar 15; 24(3):461-71. PubMed ID: 14767530
    [Abstract] [Full Text] [Related]

  • 25. Serum prostate specific antigen levels in mice bearing human prostate LNCaP tumors are determined by tumor volume and endocrine and growth factors.
    Gleave ME, Hsieh JT, Wu HC, von Eschenbach AC, Chung LW.
    Cancer Res; 1992 Mar 15; 52(6):1598-605. PubMed ID: 1371718
    [Abstract] [Full Text] [Related]

  • 26. Increased insulin-like growth factor I receptor expression and signaling are components of androgen-independent progression in a lineage-derived prostate cancer progression model.
    Krueckl SL, Sikes RA, Edlund NM, Bell RH, Hurtado-Coll A, Fazli L, Gleave ME, Cox ME.
    Cancer Res; 2004 Dec 01; 64(23):8620-9. PubMed ID: 15574769
    [Abstract] [Full Text] [Related]

  • 27. Suppression of LNCaP prostate cancer xenograft tumors by a prostate-specific protein tyrosine phosphatase, prostatic acid phosphatase.
    Igawa T, Lin FF, Rao P, Lin MF.
    Prostate; 2003 Jun 01; 55(4):247-58. PubMed ID: 12712404
    [Abstract] [Full Text] [Related]

  • 28. Relaxin becomes upregulated during prostate cancer progression to androgen independence and is negatively regulated by androgens.
    Thompson VC, Morris TG, Cochrane DR, Cavanagh J, Wafa LA, Hamilton T, Wang S, Fazli L, Gleave ME, Nelson CC.
    Prostate; 2006 Dec 01; 66(16):1698-709. PubMed ID: 16998820
    [Abstract] [Full Text] [Related]

  • 29. Overexpression of bcl-2 protects prostate cancer cells from apoptosis in vitro and confers resistance to androgen depletion in vivo.
    Raffo AJ, Perlman H, Chen MW, Day ML, Streitman JS, Buttyan R.
    Cancer Res; 1995 Oct 01; 55(19):4438-45. PubMed ID: 7671257
    [Abstract] [Full Text] [Related]

  • 30. Inhibition of caspases by cytokine response modifier A blocks androgen ablation-mediated prostate cancer cell death in vivo.
    Srikanth S, Kraft AS.
    Cancer Res; 1998 Feb 15; 58(4):834-9. PubMed ID: 9485043
    [Abstract] [Full Text] [Related]

  • 31. Heat shock protein expression independently predicts clinical outcome in prostate cancer.
    Cornford PA, Dodson AR, Parsons KF, Desmond AD, Woolfenden A, Fordham M, Neoptolemos JP, Ke Y, Foster CS.
    Cancer Res; 2000 Dec 15; 60(24):7099-105. PubMed ID: 11156417
    [Abstract] [Full Text] [Related]

  • 32. Butyrate analogue, isobutyramide, inhibits tumor growth and time to androgen-independent progression in the human prostate LNCaP tumor model.
    Gleave ME, Sato N, Sadar M, Yago V, Bruchovsky N, Sullivan L.
    J Cell Biochem; 1998 Jun 01; 69(3):271-81. PubMed ID: 9581866
    [Abstract] [Full Text] [Related]

  • 33. Identification of EP4 as a potential target for the treatment of castration-resistant prostate cancer using a novel xenograft model.
    Terada N, Shimizu Y, Kamba T, Inoue T, Maeno A, Kobayashi T, Nakamura E, Kamoto T, Kanaji T, Maruyama T, Mikami Y, Toda Y, Matsuoka T, Okuno Y, Tsujimoto G, Narumiya S, Ogawa O.
    Cancer Res; 2010 Feb 15; 70(4):1606-15. PubMed ID: 20145136
    [Abstract] [Full Text] [Related]

  • 34. Beyond simple castration: targeting the molecular basis of treatment resistance in advanced prostate cancer.
    Gleave M, Miyake H, Chi K.
    Cancer Chemother Pharmacol; 2005 Nov 15; 56 Suppl 1():47-57. PubMed ID: 16273354
    [Abstract] [Full Text] [Related]

  • 35. [Inhibitory effect of silencing STAT3 gene with short hairpin RNA mediated by polyamidoamine dendrimers on growth of prostate cancer].
    Zhao WM, Xiu YC, Xu Y, Wang YM, Cheng ZK, Yu Q, Kong DL.
    Zhonghua Zhong Liu Za Zhi; 2007 Aug 15; 29(8):575-9. PubMed ID: 18210874
    [Abstract] [Full Text] [Related]

  • 36. G-quartet oligonucleotides: a new class of signal transducer and activator of transcription 3 inhibitors that suppresses growth of prostate and breast tumors through induction of apoptosis.
    Jing N, Li Y, Xiong W, Sha W, Jing L, Tweardy DJ.
    Cancer Res; 2004 Sep 15; 64(18):6603-9. PubMed ID: 15374974
    [Abstract] [Full Text] [Related]

  • 37. MicroRNA-616 induces androgen-independent growth of prostate cancer cells by suppressing expression of tissue factor pathway inhibitor TFPI-2.
    Ma S, Chan YP, Kwan PS, Lee TK, Yan M, Tang KH, Ling MT, Vielkind JR, Guan XY, Chan KW.
    Cancer Res; 2011 Jan 15; 71(2):583-92. PubMed ID: 21224345
    [Abstract] [Full Text] [Related]

  • 38. Antisense Bcl-2 oligodeoxynucleotides inhibit progression to androgen-independence after castration in the Shionogi tumor model.
    Miyake H, Tolcher A, Gleave ME.
    Cancer Res; 1999 Aug 15; 59(16):4030-4. PubMed ID: 10463603
    [Abstract] [Full Text] [Related]

  • 39. Inhibition of interleukin-6 with CNTO328, an anti-interleukin-6 monoclonal antibody, inhibits conversion of androgen-dependent prostate cancer to an androgen-independent phenotype in orchiectomized mice.
    Wallner L, Dai J, Escara-Wilke J, Zhang J, Yao Z, Lu Y, Trikha M, Nemeth JA, Zaki MH, Keller ET.
    Cancer Res; 2006 Mar 15; 66(6):3087-95. PubMed ID: 16540658
    [Abstract] [Full Text] [Related]

  • 40. Protective role of Hsp27 protein against gamma radiation-induced apoptosis and radiosensitization effects of Hsp27 gene silencing in different human tumor cells.
    Aloy MT, Hadchity E, Bionda C, Diaz-Latoud C, Claude L, Rousson R, Arrigo AP, Rodriguez-Lafrasse C.
    Int J Radiat Oncol Biol Phys; 2008 Feb 01; 70(2):543-53. PubMed ID: 17980509
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 33.